Itovebi Side Effects

Generic name: inavolisib

Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.

Note: This document provides detailed information about Itovebi.

Applies to inavolisib: oral tablets Side Effects associated with inavolisib. Some dosage forms listed on this page may not apply specifically to the brand name Itovebi.

Applies to inavolisib: oral tablets.

Side effects include:

Most common adverse reactions (≥20%), including laboratory abnormalities: decreased neutrophils, decreased hemoglobin, increased fasting glucose, decreased platelets, decreased lymphocytes, stomatitis, diarrhea, decreased calcium, fatigue, decreased potassium, increased creatinine, increased ALT, nausea, decreased sodium, decreased magnesium, rash, decreased appetite, COVID-19 infection, headache.

For healthcare professionals

Applies to inavolisib: oral tablet.

General adverse events

The most common adverse reactions occurring in at least 20% of patients included decreased neutrophils, decreased hemoglobin, increased fasting glucose, decreased platelets, decreased lymphocytes, stomatitis, diarrhea, decreased calcium, fatigue, decreased potassium, increased creatinine, increased ALT, nausea, decreased sodium, decreased magnesium, rash, decreased appetite, COVID-19 infection, and headache.^[Ref]

Dermatologic

• Very common (10% or more): Rash (26%), alopecia (19%), dry skin/fissures/xerosis/xeroderma (13%)

Endocrine

• Very common (10% or more): Increased fasting glucose levels (85%)

Gastrointestinal

• Very common (10% or more): Stomatitis (51%), diarrhea (48%), nausea (28%), increased lipase (16%), vomiting (15%)
• Frequency not reported: Abdominal pain, dysgeusia, dyspepsia

Stomatitis included aphthous ulcer, glossitis, glossodynia, lip ulceration, mouth ulceration, and mucosal inflammation.

Hematologic

• Very common (10% or more): Decreased total and absolute neutrophils (95%), decreased hemoglobin (88%), decreased platelets (84%), decreased absolute lymphocytes (72%)

Hepatic

• Very common (10% or more): Increased ALT (34%)

Metabolic

• Very common (10% or more): Decreased appetite (24%), decreased calcium (42%), decreased potassium (38%), decreased sodium (28%), decreased magnesium (27%)

Nervous system

• Very common (10% or more): Headache (22%)

Ocular

• Frequency not reported: Dry eye

Other

• Very common (10% or more): Fatigue (38%), COVID-19 infection (23%), decreased weight (17%)

Renal

• Very common (10% or more): Increased creatinine (38%), urinary tract infection (15%)

See also:

Further information

Itovebi side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer